The 13 linked references in paper M. Naumtseva S., B. Belov S., E. Aleksandrova N., G. Tarasova M., A. Novikov A., D. Karateev E., E. Luchikhina L., M. Cherkasova V., Yu. Murav'ev V., М. Наумцева С., Б. Белов С., Е. Александрова Н., Г. Тарасова М., А. Новиков А., Д. Каратеев Е., Е. Лучихина Л., М. Черкасова В., Ю. Муравьев В. (2016) “Оценка клинической эффективности, иммуногенности и безопасности 23-валентной пневмококковой вакцины у больных ревматоидным артритом // Assessment of clinical and immunological efficacy and safety of 23-valent pneumococcal vaccine in patients with rheumatoid arthritis” / spz:neicon:pulmonology:y:2015:i:6:p:720-724

  1. Curtis J.R., Yang S., Patkar N.M. et al. Risk of hospitalized bacterial infections associated with biologic treatment among U.S. veterans with rheumatoid arthritis. Arthritis Care Res.2014; 66 (7): 990–997. DOI: 10.1002/acr.22281.
  2. Widdifield J., Bernatsky S., Paterson J.M. et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res. 2013; 65 (3): 353–361. DOI: 10.1002/acr.21812.
  3. Assen S., Agmon-Levin N., Elkayam O. et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann. Rheum. Dis.2011; 70 (3): 414–422. DOI: 10.1136/ard.2010.137216.
  4. Singh J.A., Furst D.E., Bharat A. et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res.2012; 64 (5): 625–639. DOI: 10.1002/ acr.21641.
  5. Rubin L.G., Levin M.J., Ljungman P. et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin. Infect. Dis.2014; 58 (3): e44–100. DOI: 10.1093/cid/cit684.
  6. Lanternier F., Henegar C., Mouthon L. et al. Low influenzavaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease. Ann. Rheum. Dis. 2008; 67 (7): 1047. DOI: 10.1136/ard.2007.081703. http://journal.pulmonology.ru723 Наумцева М.С. и др. Оценка клинической эффективности и безопасности 23-валентной пневмококковой вакцины
  7. 1136/annrheumdis-2013-204223. 10. Aletaha D., Neogi T., Silman A.J. et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology / European League Against Rheumatism collaborative initiative. Arthritis Rheum.2010; 62 (9): 2569–2581. DOI: 10.1002/art.27584.
  8. Mori S., Ueki Y., Akeda Y. et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann. Rheum. Dis. 2013; 72 (8): 1362–1366. DOI: 10.1136/annrheumdis-2012-202658.
  9. Bingham C.O. 3rd, Rizzo W., Kivitz A. et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann. Rheum. Dis.2015; 74 (5): 818–822. DOI: 10.1136/annrheumdis-2013-204427.
  10. Bengtsson C., Kapetanovich M.C., Kallberg H. et al. Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann. Rheum. Dis. 2010; 69 (10): 1831–1833. DOI: 10.1136/ard.2010.129908.
  11. Hmamouchi I., Winthrop K., Launay O. et al. Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort. Vaccine. 2015; 33 (12): 1446–1452. DOI: 10.1016/j.vaccine. 2015.01.065.
  12. Kapetanovich M.С., Saxne T., Sjoholm A. et al. Influence of methotrexat, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide in patients with rheumatoid arthritis. Rheumatology. 2006; 45: 106–111. DOI: 10.1093/rheumatology/kei193.
  13. Mori S., Ueki Y., Akeda Y. et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann. Rheum. Dis.2013; 72 (8): 1362–1366. DOI: 10.1136/annrheumdis-2012-202658.